HRT in India: questions that matter more than a one-size-fits-all answer

1. Are your symptoms affecting everyday life?

Hot flushes during a commute, night sweats that interrupt sleep, or vaginal discomfort need not be dismissed as something to tolerate. But menopause does not create the same treatment needs for everyone. Whether systemic hormone replacement therapy (HRT) is appropriate depends on which symptoms are troublesome, their impact, your health history and your preferences.

Systemic HRT delivers hormones throughout the body and is an effective treatment for menopausal hot flushes and night sweats. Sleep may improve when these symptoms settle. It can also reduce bone loss while being taken. It is not a universal treatment for fatigue, low mood or every midlife change, and should not be started simply to prevent heart disease or dementia.

Some people prefer non-hormonal treatments or cannot safely use systemic HRT. Menopause-specific cognitive behavioural therapy and certain prescription medicines may help. Heavy bleeding, thyroid problems, anaemia and other conditions can overlap with menopause symptoms, so assessment should not assume hormones explain everything.

2. Do you need systemic treatment or local vaginal estrogen?

Vaginal dryness, burning, pain during sex and some urinary symptoms may respond to local vaginal estrogen rather than systemic HRT. Local treatment acts mainly in vaginal and nearby tissues, with much less absorption into the bloodstream. It does not treat hot flushes.

Vaginal moisturisers and lubricants are useful non-hormonal options. Local estrogen may be considered if symptoms persist, and may sometimes be used alongside systemic HRT. Low-dose vaginal estrogen generally does not require an added progestogen, unlike systemic estrogen in someone with a uterus. Any unexpected vaginal bleeding still needs assessment.

A personal history of breast cancer changes this discussion. Non-hormonal options are usually tried first; persistent symptoms may justify considering vaginal estrogen through shared decision-making, involving the cancer team where appropriate, especially during aromatase inhibitor treatment. Low absorption does not mean every situation is risk-free.

3. Why do your uterus and treatment route matter?

If you have a uterus, systemic estrogen usually needs an appropriate progestogen to protect the womb lining. Estrogen alone can cause the lining to thicken and increase endometrial cancer risk. After a total hysterectomy, estrogen alone is often suitable, although circumstances such as previous endometriosis may require specialist advice.

The pattern of progestogen treatment depends partly on whether periods are continuing and how long it has been since the last period. Tell the clinician about hysterectomy, endometrial ablation or any hormonal intrauterine device: these details affect the plan.

Oral estrogen passes through the liver and increases venous blood clot risk. Transdermal estrogen, delivered through a patch or gel, generally has a more favourable clot-risk profile and may be preferred when relevant risk factors exist. However, a patch is not automatically safe for everyone, and choosing it does not remove other HRT considerations, including breast cancer risk.

4. Which parts of your history change the decision?

Bring details of previous breast cancer, blood clots in the leg or lung, stroke, heart disease, liver disease and unexplained vaginal bleeding. A personal history of breast cancer usually means systemic HRT is avoided. A previous clot needs specialist assessment rather than simply switching from tablets to a patch.

Age and time since menopause matter. For many otherwise healthy people starting before age 60 or within ten years of menopause, the benefit–risk balance can be favourable for troublesome symptoms. These are discussion points, not eligibility guarantees. Starting later needs particularly careful assessment. Menopause before age 45 also deserves a different discussion about longer-term health.

Breast cancer risk varies with the type and duration of systemic HRT; combined estrogen–progestogen treatment carries a different risk profile from estrogen alone. Family history, blood pressure, smoking, weight, medicines and personal priorities all help shape an informed choice.

5. What about “bioidentical” hormones and contraception?

“Bioidentical” is a marketing term as well as a description of hormone structure. Regulated medicines can contain hormones structurally identical to those made by the body. Custom-compounded products are not proven safer or more effective, and may have less consistent quality, strength and safety evidence. Saliva-based hormone testing is not a reliable basis for tailoring menopause treatment.

HRT is not contraception. Ovulation can still occur during perimenopause, even with irregular periods. Discuss pregnancy prevention separately, along with treatment availability, affordability and follow-up. Review is commonly arranged around three months after starting or changing HRT, then annually, or sooner if problems arise.

6. When should you seek care?

Arrange assessment for bleeding after menopause, unexplained bleeding before starting HRT, or persistent, heavy or new bleeding during treatment. Seek prompt review for a new breast lump. Sudden breathlessness, chest pain, one-sided leg swelling or stroke-like symptoms require emergency care.

• Match treatment to the symptoms that matter to you.
• Distinguish systemic HRT from local vaginal estrogen.
• Discuss uterus protection, route and personal cancer or clot history.
• Review benefits, side effects and contraception rather than continuing automatically.

Sources consulted: NICE NG23, Menopause: identification and management — https://www.nice.org.uk/guidance/ng23; Indian Menopause Society clinical practice guidance — https://pmc.ncbi.nlm.nih.gov/articles/PMC7688016/.

For a personalised menopause consultation with Dr. Munawwer Sana at Apollo Fertility, Kondapur, Hyderabad, or online, book an appointment.